Previous Close | 0.6890 |
Open | 0.6700 |
Bid | 0.6761 x 200 |
Ask | 0.7400 x 200 |
Day's Range | 0.6700 - 0.7300 |
52 Week Range | 0.5600 - 3.1000 |
Volume | |
Avg. Volume | 411,996 |
Market Cap | 90.94M |
Beta (5Y Monthly) | 2.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.5300 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for VAXX
Presentation will address the Company’s clinical data in Parkinson’s diseaseCAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease at the Annual Academy of Neurology (AAN) 2024 Annual Meeting, taking place April 13-18, 2024 virtually and in Denver, Colorado. Presentation details are as follows:Oral Pr
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. “2024 will prove to be a critical year for Vaxxinity as we refocus our efforts on our neurodegeneration programs and move closer to obtaining our company’s first approval,” said Mei Mei Hu, CEO o
UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patientsLISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX), a U.S. company pioneering the development of a new class of medicines, announced positive clinical data from its UB-312 program in Parkinson’s disease (PD) presented by Jean-Cosme Dodart, PhD, SVP of Research at Vaxxinity in an oral session at the AD/PD™ 2024 International Conference on A